To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

Exclusion Criteria

• •1. Subjects who are pregnant or intend to become pregnant during the study
• •2. Subject with positive hepatitis panel and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody \[anti-HCV\]), and / or a positive Human immunodeficiency virus (HIV) antibody.
• •3. Known sensitivity to any component of the study drug or previous hypersensitivity reaction or other clinically significant reaction to IV medications, biologic therapy or IV radiocontrast agents.
• •4. Active infection requiring systemic treatment
• •5. Planned surgery during the study period or had undergone major surgery within the 60 Days prior to the Screening visit.